LifeStance Health Group, Inc. (LFST) shares plummeted 7.63% in pre-market trading on Wednesday, despite reporting better-than-expected first-quarter results. The mental healthcare provider's weak second-quarter guidance appears to have overshadowed its positive Q1 performance.
For the first quarter of 2025, LifeStance reported revenue of $333 million, slightly beating the IBES estimate of $332.9 million. The company also surprised investors with a net income of $700,000, compared to the expected loss of $14.5 million. Adjusted EBITDA came in at $34.6 million, surpassing the estimated $30.2 million.
However, LifeStance's outlook for the second quarter fell short of expectations. The company forecasts Q2 revenue between $332 million and $352 million, with the midpoint below the IBES estimate of $352.8 million. Additionally, LifeStance reiterated its full-year 2025 revenue guidance of $1.40 billion to $1.44 billion, which may have disappointed investors hoping for an upgrade following the strong Q1 results. This conservative outlook, coupled with the lower-than-expected Q2 guidance, likely triggered the sell-off in pre-market trading, despite the company's solid Q1 performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.